The funding will take home & clinical tests through clinical trials and submissions for FDA clearance.
The drug is an alternative to opiates.
Novel prodrug with unique mechanism of action takes on the opioid crisis
The ultimate goal is to 3D print the entire vascular system of a kidney in 12 hours or less.
Prellis is developing ultra-fast high-resolution holographic laser printing for creating human organs and tissues.
The two companies will advance the $1.2 million high-precision Holograph-X Bioprinter
Channel Medsystems has developed the Cerene® Cryotherapy Device to treat heavy menstrual bleeding.
Zenflow's technology relieves urinary blockage caused by enlarged prostate. The funding will accelerate progress to market.
Raydiant was a 2017 Rosenman Innovator.
Green Sun, a 2017 Rosenman Innovator, is developing a much-improved brace for children with scoliosis.
Respira is building a service platform of wearable devices and adaptive digital algorithms to improve the delivery of Chronic Lower Respiratory Disease care.
The biggest opportunity for the 600-person company is to produce entirely new products that are untethered to traditional petroleum-based manufacturing.
Science Magazine profiles Zymergen's AI/robotics technology for microbe engineering.
True North is a Mission Bay Capital portfolio company pursuing therapies that target the complement system to treat rare diseases.
Symic recently graduated from the QB3@953 incubator after several years' residence.
Principia is a spinoff from Jack Taunton’s lab at UCSF.
Principia plans to list on the Nasdaq under the symbol PRNB.
The collaboration is aimed at developing first-in-class oral therapies that bring the power of proteasome inhibition safely into the field of immunology.
eFFECTOR, in Mission Bay Capital's portfolio, is a leader in the development of selective translation regulators for the treatment of cancer.
eFT508 and avelumab are immunotherapies, designed to harness the body's own immune system in fighting cancer.
Atreca uses its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types.
Atreca was one of the first companies in Mission Bay Capital’s portfolio.
Atreca was an early portfolio company of QB3-affiliated Mission Bay Capital.
Atreca will apply its Immune Repertoire Capture® technology to generate sequences of native antibodies and TCRs from patients.
Sillajen is a former resident of the Mission Bay Innovation Center.
The collaboration will advance polypharmacology in drug discovery using AI-augmented technology.
The partnership will develop intravitreal gene therapeutics for patients using 4DMT-proprietary AAV vectors.
Graphwear's wearable device employs an ultrathin layer of graphene in its sensor.
The partnership will yield an advanced information technology system for the forward engineering of microbial systems.
TeselaGen and Dow collaborate on a state-of-the-art biological design automation platform
The financing will help the company advance its Smart Growth Factor™ pipeline into the clinic.
Modus is a modular 'drop in' technology to monetize refinery offgas streams.
BillionToOne’s first product is a non-invasive prenatal test for recessively inherited single gene disorders.
Wary of failing in public, they worked in stealth at the QB3 Garage for 5 years.
Not many synbio scientists have seen the results of their research onstage at Fashion Week in Paris.
Pivot is partnering with Monsanto, a Bayer company, to help US soybean farmers boost crop harvests.
Pivot’s microbial technology will allow farmers to reduce the use of fertilizers, which can generate potent greenhouse gases.
Pivot’s crop probiotics prevent the nitrate runoff that causes algal blight in waterways.